The current evidence points to potential therapeutic opportunities arising from exploiting SMUG1-mediated BER to induce synthetic lethality in combination with PARP and ATR inhibitors, particularly in BRCA1/2-deficient tumours. The gene discussed is SMUG1; the disease is neoplasm.